C. Foster

发表

Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer–specific death in patients receiving salvage radiation therapy following radical prostatectomy

R. Mehra, W. Jackson, F. Feng, 2013, Cancer.

Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.

R. Mehra, H. Sandler, W. Jackson, 2013, International journal of radiation oncology, biology, physics.

Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer.

R. Weichselbaum, S. Pitroda, C. Foster, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Punctate Anetoderma After Colony-Stimulating Factor 1 Receptor and Programmed Cell Death 1 Blockade With Irradiation: Clinicopathologic Characterization of a Novel Eruption.

J. Luke, Y. Zha, S. Chmura, 2021, JAMA dermatology.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

E. Vokes, T. Seiwert, D. Haraf, 2019, Annals of Oncology.

T. Seiwert, R. Brisson, Y. Tan, 2021, Cancer.

Is It Worth It? Consequences of Definitive Head and Neck Reirradiation.

R. Weichselbaum, N. Lee, S. Yom, 2020, Seminars in radiation oncology.

Putting the "BR" in SBRT.

S. Chmura, C. Foster, 2018, International journal of radiation oncology, biology, physics.

Erratum: ERRATUM: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (Ann Oncol (2019) DOI: 10.1093/annonc/mdy522)

E. Vokes, T. Seiwert, D. Haraf, 2019 .

Oligometastatic prostate cancer: Reality or figment of imagination?

R. Weichselbaum, S. Pitroda, C. Foster, 2018, Cancer.

Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.

A. Pearson, N. Cipriani, E. Vokes, 2021, Oral oncology.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

E. Vokes, T. Seiwert, D. Haraf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors

M. Ratain, R. Weichselbaum, E. Vokes, 2021, Clinical Cancer Research.

Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Post-Treatment Functional Outcomes.

E. Vokes, T. Seiwert, D. Haraf, 2020, International journal of radiation oncology, biology, physics.

Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease

R. Weichselbaum, S. Pitroda, C. Foster, 2020, Cancer journal.

Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.

D. Sher, M. Spiotto, M. Koshy, 2019, Lung cancer.

Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features.

R. Weichselbaum, S. Pitroda, C. Foster, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience.

E. Vokes, T. Seiwert, D. Haraf, 2018, Oral oncology.

Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy

Larissa V Furtado, N. Hyman, S. Xiao, 2018, PloS one.

Linearly Accelerating Toward Gender Equity in Radiation Oncology.

Y. Hasan, A. McCall, C. Son, 2019, International journal of radiation oncology, biology, physics.

Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization

G. Merrick, P. McLaughlin, R. Dess, 2019, American journal of clinical oncology.

Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy.

W. Jackson, F. Feng, D. Hamstra, 2014, Practical radiation oncology.

A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy

H. Sandler, W. Jackson, T. Morgan, 2013, Radiation oncology.

Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis

R. Weichselbaum, D. Sher, M. Spiotto, 2019, Radiation oncology.

Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy

W. Jackson, F. Feng, D. Hamstra, 2014, Radiation oncology.

The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer.

W. Jackson, F. Feng, D. Hamstra, 2013, International journal of radiation oncology, biology, physics.

OPTIMA—A Phase 2 Trial of Induction Chemotherapy Response-Stratified Radiation Therapy Dose and Volume De-escalation for HPV+ Oropharyngeal Cancer: Efficacy, Toxicity, and HPV Subtype Analysis

E. Vokes, T. Seiwert, D. Haraf, 2018 .

Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.

H. Sandler, W. Jackson, F. Feng, 2016, European urology.

In Reply to Trombetta.

Y. Hasan, A. McCall, C. Son, 2019, International Journal of Radiation Oncology, Biology, Physics.

Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy.

A. Pearson, E. Vokes, T. Seiwert, 2018 .

Hafnium oxide nanoparticles activated by SABR in combination with PD-1 inhibitors for the treatment of patients with advanced HNSCC or NSCLC: A phase I/II trial.

S. Bonvalot, T. Seiwert, V. Calugaru, 2019, Journal of Clinical Oncology.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

E. Vokes, T. Seiwert, D. Haraf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.